Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05805501 · ClinicalTrials.gov registry record · Phase 2
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
A Phase 2 study of Renal Cell Carcinoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
- 20
- Study locations
NCT05805501 is a Phase 2 study of Renal Cell Carcinoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 199 participants, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT05805501, a Phase 2 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Axitinib
- DRUG Tiragolumab
- DRUG Tobemstomig
Study Locations (20)
Other
- Peking University First Hospital - Beijing
- Beijing Cancer Hospital - Beijing
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School - Nanjing
- Tianjin Cancer Hospital - Tianjin
- Institut Sainte Catherine - Avignon
- CHU Besançon - Hôpital Jean Minjoz - Besançon
- CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre - Bordeaux
- Centre Francois Baclesse - Caen
- Centre Leon Berard - Lyon
- Institut Gustave Roussy - Villejuif
- Universitätsklinikum "Carl Gustav Carus" - Dresden
Tennessee
- SCRI Oncology Partners - Nashville
- Vanderbilt University Medical Center - Nashville
Alabama
- University of Alabama at Birmingham - Birmingham
California
- UC Irvine Medical Center - Orange
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Georgia
- Emory University - Atlanta
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05805501
The ClinicalTrials.gov registry entry for NCT05805501 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (17% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05805501 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Tennessee, Alabama.
Frequently Asked Questions
What is clinical trial NCT05805501 about?
NCT05805501 is a clinical study titled "A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma". This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carci...
What is the current status of trial NCT05805501?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2023-04-21. Estimated completion is 2026-10-31.
What conditions does trial NCT05805501 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT05805501?
The interventions under investigation include: Pembrolizumab (DRUG), Axitinib (DRUG), Tiragolumab (DRUG), Tobemstomig (DRUG).
Who is sponsoring clinical trial NCT05805501?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05805501 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.